Atara biotherapeutics to announce completion of ata188 phase 2 embold study interim analysis on tuesday, july 12, 2022

South san francisco, calif.--(business wire)--atara biotherapeutics, inc. (nasdaq: atra), a leader in t-cell immunotherapy, leveraging its novel allogeneic epstein-barr virus (ebv) t-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the company will disclose its completion of the ata188 phase 2 embold study interim analysis via press release after market close on tuesday, july 12, 2022. following the release, the company will hos
ATRA Ratings Summary
ATRA Quant Ranking